Mirae Asset Global ETFs Holdings
CRVS icon

Mirae Asset Global ETFs Holdings’s Corvus Pharmaceuticals CRVS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$548K Buy
38,152
+5,743
+18% +$91.7K ﹤0.01% 1848
2025
Q4 		$248K Buy
32,409
+4,884
+18% +$38.5K ﹤0.01% 2248
2025
Q3 		$203K Sell
27,525
-1,136
-4% -$5.81K ﹤0.01% 2311
2025
Q2 		$115K Buy
+28,661
New +$104K ﹤0.01% 2540

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CRVS Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Corvus Pharmaceuticals (CRVS) stake by 18% in Q1 2026, buying an estimated $91.7K and bringing the position to 38,152 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

Mirae Asset Global ETFs Holdings first reported a position in CRVS in Q2 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 38,152 shares of Corvus Pharmaceuticals worth $548K as of Q1 2026.
  • Mirae Asset Global ETFs Holdings bought 5,743 Corvus Pharmaceuticals shares in Q1 2026, an estimated $91.7K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #1848 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.